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إدارة التخدير ملريض الوذمة الوعائية الوراثية مع إعطاء اجلرعة الوقائية من 
مثبط C1 اسرتيز
تقرير حالة ومراجعة األدبيات
اأرفيند نارايانان، روهيت ديت، �شاناث كومار بريور، براديبتا بهاكتا، �شينا كريو�شنان �رسينيفا�شان
امللخ�ص: الوذمة الوعائية الوراثية هو ا�شطراب نادر ناجم عن عوز يف مثبط C1 ا�شرتيز. ال�شدمات الطفيفة وال�شغط النف�شي هي االأ�شباب 
يوؤدي لظهور وذمة  املن�شبط. هذا مما  املفرط غري  للرباديكينني  واالإفراز  النظام  لتفعيل  االت�شال  لل�رسوع يف  توؤدي  التي  �شيوعا  االأكرث 
وعائية، وهو رد فعل االأوعية الدموية يف الطبقات العميقة من اجللد واالأغ�شية املخاطية، مع تو�شع االأوعية وزيادة النفاذية مما يوؤدى اإىل 
تورم االأن�شجة. ميكن اأن حتدث الوذمة الوعائية احلادة يف الفرتة املحيطة باجلراحة، مما قد يوؤدى اإىل ان�شداد جمرى الهواء م�شببا الوفاة. 
يف هذه التادة تاأهيل االأ�شنان حلالة طفل م�شاب بالوذمة الوعائية الوراثية، مع مراجعة االأدبيات ذات ال�شلة.
مفتاح الكلمات: التخدير، وذمة وعائية وراثية، عوز مثبط C1 ا�شرتيز، تقرير حالة ،عمان.
abstract: Hereditary angioedema (HAE) is a rare disorder caused by a deficiency of C1 esterase inhibitor. Minor 
trauma and emotional stress are the most common initiating events leading to contact system activation and 
excessive uncontrolled bradykinin release. This manifests as angioedema, a vascular reaction of the deeper layers of 
the skin and mucous membranes, with vasodilatation and increased permeability resulting in tissue swelling. Severe 
angioedema can occur in the perioperative period, leading to fatal airway obstruction. We describe the anaesthetic 
management of a child with HAE for dental rehabilitation and provide an review of the relevant literature.
Keywords: Anesthesia; Hereditary angioedema; C1 esterase inhibitor deficiency; Case Report; Oman.
Anaesthesia Management of a Patient with 
Hereditary Angioedema with Prophylactic 
Administration of C1 Esterase Inhibitor
Case report and literature review
*Aravind Narayanan, Rohit R. Date, Sanathkumar Birur, Pradipta Bhakta, Sinnakirouchenane Srinivasan 
online case report
Hereditary angioedema (HAE) is caused by a deficiency of C1 esterase inhibitor (C1-INH). C1-INH is a serine 
protease which inhibits "Activated Factor XIIa" and 
"Kallikrein". Deficiency of this key inhibitor leads 
to uncontrolled activation of the Contact System 
thereby generating profuse amounts of Bradykinin; 
which is a potent local vasodilator. Trivial 
stressors can then lead to uncontrolled bradykinin 
production, with increased vascular permeability of 
deeper tissues. Airway oedema and hypovolemic 
shock due to the tissue leak of fluids are especially 
significant in the perioperative period, challenging 
even the most experienced anaesthesiologist. 
Case Report
A 6-year-old girl weighing 15 Kg who had been 
diagnosed with C1-INH deficiency was admitted to 
Sultan Qaboos University Hospital (SQUH), Oman, 
for dental rehabilitation from multiple dental caries. 
From two years of age, there had been episodes of 
abdominal pain and facial swelling, which were 
self-limiting within 2 to 3 days. Subsequently, 
there were more aggressive attacks with acute 
dyspnoea, dysphagia and diarrhoea combined 
with the progressive swelling of the right side of 
the neck for which she required admission to the 
intensive care unit (ICU) for observation; however, 
no endotracheal intubation was required.
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At 3 years old, she was diagnosed by the SQUH 
Immunology Team with HAE type II and received 
500 units of plasma-derived C1-INH concentrate 
(pdC1INH) (Berinert P®, CSL Behring, Marburg, 
Germany) for the successful management of 
severe periorbital swelling and subacute intestinal 
obstruction. Laboratory investigations revealed low 
complement 4 (C4) levels of 0.06 g/L (reference 
value: 0.16–0.38 g/L) and high C1-INH antigenic 
levels of 694 mg/L (reference value: 210–345 mg/L). 
However, the functional activity of C1-INH was only 
22% at 4.9 U/ml (reference value: 17.2–27.4) and 
C1 INH-specific activity was 7.0 U/mg (reference 
value: 67.4–93.6).
Her pre-anaesthetic evaluation was otherwise 
unremarkable. The plasma-derived C1-INH 
(pdC1-INH) concentrate was administered 
prophylactically, one hour preoperatively. Two 
additional doses of pdC1-INH and fresh frozen 
plasma (FFP) were kept ready.
With difficult airway equipment, an 
emergency tracheostomy kit and an experienced 
otorhinolaryngologist present, the anaesthesia 
was induced with propofol with 2.5 mg/Kg 
and fentanyl at 2 µg/Kg. Under neuromuscular 
blockade, cisatracurium 0.1 mg/Kg, the airway was 
secured via the nasal route using a cuffed Ring-
Adair-Elwyn (RAE) endotracheal tube, and a throat 
pack was inserted using minimal manipulation of 
the oropharyngeal airway. A paracetamol (375mg) 
suppository was placed rectally. Her intraoperative 
course was uneventful. Residual muscle paralysis 
was reversed using neostigmine (0.05 mg/Kg) 
and glycopyrolate (0.01 mg/Kg). After ensuring a 
positive audible air leak with cuff deflation, the 
trachea was extubated when she became fully 
awake so as to rule out any airway oedema. She 
was transferred to the Pediatric Intensive Care 
Unit for further observation. Apart from a mild 
lip swelling which persisted for a few hours 
post-operatively, there was no other complication. 
She was discharged after two days.
Discussion
HAE is an uncommon hereditary disorder 
(1:10,000–150,000) caused by the congenital 
deficiency of C1-INH, which inhibits function in 
three different pathways: the complement system, 
the fibrinolytic system and the contact activation 
system, in which C1-INH inhibits both activated 
factor XIIa and kallikrein in the ultimate cascade to 
the production of bradykinin.1,2 The uncontrolled 
release of bradykinin (a vasoactive peptide) is 
central to the pathophysiology of HAE.3,4 Excessive 
bradykinin eventually leads to vasodilatation and 
microvascular fluid leakage with subcutaneous and 
mucosal oedema.
HAE has autosomal dominant inheritance 
with mutations of the HAE-C1-INH gene on 
chromosome 11q12-q13.1.5 Three forms of HAE 
have been described: type I with low C1-INH 
antigenic protein and functional activity (85% 
of cases), type II with normal or elevated protein 
but low C1-INH function (15% of cases), and type 
III HAE with normal C1-INH. Type III is further 
classified into two types: HAE-XII, a familial 
oestrogen-dependent variety, described only in 
females and thought to be due to the mutation of 
coagulation factor XII, and HAE-unknown, with an 
as yet unidentified genetic defect.5–7
Most HAE patients have a positive family 
history. The age of onset is variable with laryngeal 
attacks uncommon before the age of 3 and tending 
to occur later than other symptoms.8 HAE can 
be precipitated or exacerbated by minor trauma 
(50% of cases), emotional upset (30–40% of cases), 
infection, menstruation, pregnancy, cold exposure, 
certain foods or drugs (angiotensin-converting-
enzyme inhibitors or oestrogen oral contraceptives) 
or sometimes without any obvious trigger.9 Surgical 
trauma and stress can be a potent trigger of HAE 
and fatal attacks have been reported after dental 
surgeries.10,11
Angioedema attacks typically involve the 
extremities, genitourinary tract, bowel, face, 
oropharynx or larynx. Attacks may last for 72 to 96 
hours, and are often severe and disabling. Extremity 
and/or abdominal attacks account for almost 
50% of all attacks, and more than 50% of patients 
experience at least one upper airway attack 
during their lifetime, which carries a risk of 
asphyxiation.10,12,13 Prodromal symptoms such 
as fatigue, irritability, weakness, nausea and 
erythema marginatum precede an angioedema 
attack by several hours or even a whole day in up 
to 50% of HAE patients.4 A prodromal serpiginous 
erythematous rash is sometimes seen, but pruritic 
urticaria usually makes the diagnosis of HAE 
unlikely.14 Airway obstruction can be fatal if left 
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untreated.13 Unexplained episodic mucocutaneous 
oedema in a patient with recurrent abdominal pain, 
cramps, vomiting and a lack of fever should raise 
suspicion of HAE.
A diagnosis of C1-INH deficiency requires 
laboratory confirmation with measurement of 
the C4 level, C1-INH antigenic level and C1-INH 
functional level. C4 level assessment allows excellent 
rapid screening, with nearly 100% of patients having 
a reduced C4 level during attacks. A normal C4 level 
during an attack of angioedema strongly supports 
an alternative diagnosis, whereas decreased levels 
(less than 30% of normal levels) warrants an 
assay of C1-INH. Childhood presentation, strong 
family history and a low serum level of antigenic 
C1-INH (<30% of normal levels) are diagnostic. If 
a patient’s C1-INH level is normal, or raised along 
with a low C4 level, a functional assay of C1-INH 
should be done to detect the possibility of the 
type II defect.4 Diagnostic uncertainty is higher 
in the paediatric age group because of age-related 
variations in the normal level of C1-INH.8
HAE is especially important to anaesthesiologists 
because these patients are prone to develop 
massive upper aerodigestive tract swelling and 
life-threatening airway obstruction.15 Airway 
trauma during intubation may rapidly progress to 
laryngotracheal oedema leading to a fatal airway 
obstruction, and is more prevalent in children 
who have narrow airways—a 1-mm thick oedema 
causes a 44% airway diameter reduction in 
children versus 27% in adults.16 The initial facial 
or labial oedema seen in 15–30% cases may mask 
the early indicators of airway oedema such as 
hoarseness, voice change, stridor and dyspnoea.16 
Mortality from acute laryngeal oedema is as 
high as 15–33% in undiagnosed versus 4–6% in 
diagnosed HAE patients.13 Considering the risk 
of airway compromise, all patients with HAE 
should be carefully observed for at least 36 hours 
postoperatively as the onset time can vary between 
60 minutes to 36 hours.10,17
Management of HAE consists of long-term 
prophylaxis, short-term prophylaxis and treatment 
of established acute attack. Pharmacologic agents 
are considered in patients who experience more 
than one attack per month with recurrent abdominal 
symptoms or life-threatening laryngotracheal 
symptoms.18 In addition to being efficacious 
as an on-demand treatment of attacks, pdC1-
INH is also effective for long-term prophylaxis.16 
Treatment with oral 17a-alkylated androgens like 
methyltestosterone, danazol and stanozolol may 
be useful in long-term therapy as they stimulate 
the hepatic synthesis of C1-INH. However, their 
long-term use may produce serious steroid-related 
adverse events and hepatocellular tumours; hence, 
they should be avoided in children. Antifibrinolytics 
like epsilon-aminocaproic acid and tranexamic 
acid are no longer employed because of their poor 
efficacy.16,4
Short-term prophylaxis can be achieved with 
the administration of 10–25 U/Kg of pdC1-INH 
(Berinert P®) given one hour before the procedure. 
Alternatively, an infusion of 10 mL/Kg of solvent-
treated plasma or FFP can be administered up to 
6 hours before a scheduled procedure.  Although 
FFP is a good source of C1-INH, it also contains 
kinins and uncleaved C2 and C4 which may 
exacerbate acute attacks, apart from its transfusion-
related hazards.19 FFP is less effective, having a 
shorter duration of action and requiring a longer 
time for administration. Therefore, pdC1-INH 
concentrate has emerged as the most favoured 
option for prophylaxis before any provocative 
surgical procedure.20 High-dose androgens (danazol 
6–10 mg/Kg/day in 3 divided doses) taken for 5–7 
days before and two days after the procedure is 
an alternative strategy. For emergency procedures 
and in pregnant patients, the administration of 
pdC1-INH is preferred.14,4 
For acute attacks, standard angioedema treatment 
modalities, such as epinephrine, corticosteroids or 
antihistamines, do not have a salutary effect and 
are not recommended.5 On- demand treatment 
modalities include the replacement of C1-inhibitor 
with filtered pdC1-INH (Berinert P®), bradykinin-
2-receptor inhibitor (icatibant: subcutaneous self-
administration possible; 10% recurrence after 16–
24 hours), kallikrein antagonists (ecallantide: 4–6% 
anaphylaxis chance) and a recombinant C1-INH, 
conestat alfa (Rhucin®, Pharming Group NV, Leiden, 
Netherlands) with a half-life of 3 hours.18,14,21,22 After 
administration, most patients experience relief after 
15–120 minutes but a major swelling might take up 
to 24 hours to resolve completely. Swellings respond 
more quickly when treated early in the course of the 
attack.
The pdC1-INH concentrate is preferred for 
acute attacks because of evidence of higher efficacy 
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and safety.4,14,23 It has minimal to no transfusion 
hazards and can be safely used in paediatric as well 
as pregnant patients. It causes a partial resolution 
of symptoms within 30 minutes, and a complete 
resolution in 4–24 hours.21 The normalisation of 
laryngeal oedema occurs faster than any other 
manifestations. The pdC1-INH increases C1-INH 
levels by more than 50% within 30 minutes and 
the level remains above the baseline for 3–4 days. 
Thus, it can be used to treat acute attacks as well as 
short- and long-term prophylaxis when other drugs 
are not effective. When injected slowly, pdC1-INH 
is free from any major adverse effects. Its main 
disadvantages are the high cost, limited duration 
of activity, necessity of parenteral administration 
and the possible transmission of blood-borne 
infections.4 
Because of the rarity of occurrence, reports of 
perioperative management of HAE are very limited 
in the literature.1,15,10 This makes it difficult to 
formulate any specific guidelines for anaesthetic or 
perioperative management. However International 
Consensus Guidelines have emerged in the last two 
years elucidating an algorithmic approach to the 
management of HAE.4,5 The precipitating triggers 
mentioned earlier should be avoided. Regional 
or general anaesthesia can be safely performed in 
such patients. Regional anaesthesia is preferred 
wherever possible because of the better suppression 
of the stress response and the avoidance of airway 
manipulation.2,24 There is no known contraindication 
related to the use of any of the available intravenous 
or volatile anaesthetics and neuromuscular blocking 
agents, including succinylcholine. Although tracheal 
intubation is not contraindicated, it is important to 
reduce airway manipulation to the minimum. The 
role of the laryngeal mask airway in HAE patients 
is not completely clear, but it is reasonable to 
believe that the larger contact area may aggravate 
airway oedema. A dose of an on-demand short-
term treatment drug (pdC1-INH, ecallantide or 
icatibant) or FFP should be held ready, particularly 
for dental procedures or surgical procedures that 
require intubation.11,17
Upper airway oedema is the most dangerous 
presentation of HAE and is associated with high 
mortality.4,13,17 Fatalities are most commonly seen 
after dental surgeries.11 Intubation is always the first 
choice in the case of acute airway compromise and 
should be done as early as possible. While performing 
laryngoscopy and intubation, the presence of 
difficult airway equipment and a provision for 
urgent tracheostomy or cricothyroidotomy is 
mandatory. Airway swelling may become so severe 
at times that even a tracheostomy may be ineffective 
in maintaining a patent airway.2 The presence of 
severe airway oedema, swelling and the demand 
for immediate intervention can greatly limit the 
usefulness of fiberoptic intubation.24
This patient had already been diagnosed 
with HAE with a positive history of successful 
management with pdC1-INH concentrate. The case 
was managed successfully with a multidisciplinary 
team, using pdC1-INH prophylaxis as 
recommended and extubating the patient in a 
fully-awake condition in order to avoid any airway 
complications or subsequent precipitation of an 
acute attack. The absence of any airway oedema was 
confirmed by a cuff-leak test before the extubation 
and the patient was observed strictly for the 
recommended period for the development of any 
postoperative events.25 Although the immediate 
postoperative period was uneventful, she developed 
an acute attack after two weeks. The acute relapse 
occurring two weeks after the operation is unlikely 
to have been related to perioperative events. 
Conclusion
A high index of suspicion for the early diagnosis 
and active management with pdC1-INH forms 
the cornerstone of the successful management of 
HAE cases. Successful perioperative management 
requires prophylactic pdC1-INH, diligent 
monitoring and measures to avoid airway oedema 
triggers. 
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